A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A phase 1/2 trial of Giredestrant and Abemaciclib in HR-positive / HER2-negative breast cancer, run by Genentech, Inc., now recruiting.
Overview
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer is a phase 1/2 interventional study registered as NCT07100106 by Genentech, Inc., with 285 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-08-31. Interventions recorded: GDC-4198, Giredestrant and Abemaciclib.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.